Last reviewed · How we verify
Conditioned Media
At a glance
| Generic name | Conditioned Media |
|---|---|
| Sponsor | Sukma Skin Treatment |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Mesenchymal Stem Cells (MSCs) and Conditioned Medium Mesenchymal Stem Cells as Adjuvant Therapy for Sepsis (PHASE1, PHASE2)
- Stem Cell and Conditioned Medium for Cerebral Palsy (PHASE1, PHASE2)
- Combination of Conditioned Medium and Umbilical Cord-Mesenchymal Stem Cells Therapy for Acute Stroke Infarct (PHASE1, PHASE2)
- Mesenchymal Stem Cell Therapy (MSCs) and Conditioned Medium Therapy for Osteoartrithis (PHASE1, PHASE2)
- Long-term Safety of UC-MSC Transplantation in Patients With Retinitis Pigmentosa
- Role of UC-MSC and CM to Inhibit Vision Loss in Retinitis Pigmentosa Phase I/II (PHASE2, PHASE3)
- Conditioning SCID Infants Diagnosed Early (PHASE2)
- Autologous Hair Follicle Secretome for Androgenic Alopecia (Single Site) (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Conditioned Media CI brief — competitive landscape report
- Conditioned Media updates RSS · CI watch RSS
- Sukma Skin Treatment portfolio CI